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Although Bordetella pertussis contains and transcribes loci encoding type III secretion system (TTSS)
homologues, expression of TTSS-associated proteins has been reported only for non-laboratory-adapted Irish
clinical isolates. Here we confirm such a result for clinical isolates obtained from patients treated in Argen-
tinean hospitals. Moreover, we demonstrate that the expression of TTSS-associated proteins is independent
both of the year in which the isolate was obtained and of the types of polymorphic alleles for other virulence
factors but is dependent on environmental growth conditions. Interestingly, we observed that TTSS-associated
protein expression is lost after successive in vitro passages but becomes operative again when bacteria come
into contact with the host. This in vivo activation of TTSS expression was observed not only for clinical isolates
previously adapted to the laboratory after successive in vitro passages but also for vaccine strains that did not
express the system in vitro. The reversibility of TTSS expression, demonstrated by its switching off-on when the
bacterium comes into contact with the host, appears to be an adaptive response of this pathogen.
Many bacteria can modulate host cell traits not only by
secreting proteins into the extracellular environment but also
by translocating them directly into the interiors of host cells.
One of the most widespread means for translocating bacterial
proteins into host cells is the type III secretion system (TTSS).
This system, composed of 20 to 25 proteins, is responsible for
the transport of bacterial proteins that act as powerful “effec-
tors” and take control of host cells by hijacking their intracel-
lular machinery (18). The TTSS has been identified in many
animal pathogens, such as Yersinia spp., Salmonella spp., Shi-
gella spp., enteropathogenic and enterohemorrhagic Esche-
richia coli (e.g., O157:H7), Pseudomonas aeruginosa, Vibrio
parahaemolyticus, Bordetella spp., and Chlamydia spp. (6, 16,
21, 38). Certain bacteria, such as Salmonella enterica serovar
Typhimurium, Yersinia pestis, and Yersinia enterocolitica, en-
code more than one TTSS (6, 16). The distribution of the TTSS
is not limited exclusively to animal pathogens; it has also been
identified in plant pathogens and certain endosymbiotic bac-
teria (22, 40, 42).
Although the sequences of many components of the TTSS
apparatus used to transport effectors are conserved among
bacteria, and some of these components are also functionally
interchangeable, the target cells respond to this kind of “injec-
tion” in different ways depending on the system involved (5, 7,
8, 17).
It is noteworthy that the effector proteins of the TTSS not
only can be translocated but also can be secreted into the
extracellular medium under appropriate laboratory conditions.
For example, the Ysc TTSS, one of the two TTSSs of Yersinia,
can secrete effector proteins into the extracellular environment
when bacteria are grown at 37°C in a medium containing a low
concentration of calcium (29). Shigella can also secrete effector
proteins when it is grown in the presence of the dye Congo red
(33). Interestingly, in the case of Bordetella pertussis, a patho-
gen that causes a resurgent respiratory disease called whooping
cough or pertussis, the conditions for secretion by the TTSS
seem to differ between the circulating clinical bacterial popu-
lation and laboratory-adapted strains (12). That is, in vitro
expression of one of the known TTSS effector proteins, Bsp22,
was detected in a significant proportion of Irish clinical isolates
but not in common laboratory-adapted strains of B. pertussis.
In parallel, by a comparative proteomic strategy, we had al-
ready obtained evidence showing that a TTSS was expressed in
one Argentinean clinical isolate but not in a Tohama phase I
strain (1). These findings are important not only because they
show new aspects of the regulation of TTSS expression but also
because they represent the first data on the functionality of the
system in B. pertussis. Although the TTSS gene cluster has been
found, and designated the bsc locus (11, 45), in three species of
the Bordetella genus, B. pertussis, B. parapertussis, and B. bron-
chiseptica, the functionality of the system has been described
only for B. bronchiseptica (27). Through this system B. bron-
chiseptica secretes Bsp22 as the most abundantly expressed
TTSS protein during in vitro growth. Bsp22 is highly immuno-
genic and has the ability to confer protection against B. bron-
chiseptica infection (28). This protein also appears to play a
role in mediating persistent infection of the lower respiratory
tract and is required for TTSS-mediated cytotoxicity toward
eukaryotic cells (28, 44).
The recently demonstrated expression of TTSS proteins in
B. pertussis clinical isolates but not in strains adapted to labo-
ratory culture conditions (12), such as vaccine strains, is an
interesting phenomenon, which should be more thoroughly
analyzed not only in the context of B. pertussis evolution in vitro
but also in the context of the reemergence of the disease. Thus,
we analyze here whether the findings of Fennelly et al. (12) can
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also be extended to other, geographically unrelated clinical
isolates and to those with different genotypes. Moreover, we
evaluate the hypotheses proposing that the differential expres-
sion of the TTSS between vaccine strains and clinical isolates
relies on bacterial adaptation to in vitro growing conditions.
Both aspects were addressed by performing assays comparing
reference and vaccine strains with clinical isolates from Argen-
tina exhibiting different allelic variants of pertactin (Prn) and
pertussis toxin (Ptx).
MATERIALS AND METHODS
Bacterial strains and culture conditions. The Bordetella strains and clinical
isolates used in this study are listed in Table 1. B. pertussis clinical isolates were
recovered from the nasopharyngeal aspirates of infants with whooping cough.
Clinical samples were collected in Argentina during the years 1969 to 2007.
Strains and isolates from glycerol stocks were cultured on Bordet-Gengou agar
(BGA; Difco) supplemented with 1% glycerol and 10% (vol/vol) defibrinated
sheep blood and were incubated at 36°C for 3 days. Then, from BGA hemolytic
colonies (a marker of the virulent state of the bacteria), bacteria were replated
in the same medium for 24 h in order to obtain B. pertussis biomass retaining
virulent characteristics. To obtain supernatant proteins, subcultures were grown
in Stainer-Scholte (SS) liquid medium (34). Mutants were selected on BGA or
SS medium supplemented with gentamicin (Gm; 10 mg ml21) and kanamycin
(Km; 75 mg ml21). To modulate virulence factor expression, bacteria were grown
in SS medium supplemented with 40 mM MgSO4 at 36°C.
For passage experiments, strains were grown at 36°C on BGA with 10%
defibrinated sheep blood until individual colonies were well-defined, and a single
colony was streaked onto a fresh plate.
Escherichia coli strains TOP10 and BL21(DE3) (both from Invitrogen) were
cultured in Luria-Bertani (LB) medium supplemented, when appropriate, with
ampicillin (Ap) and Km, at final concentrations of 100 and 50 mg/ml, respectively.
PCR amplification, cloning, and expression of recombinant His6-Bsp22. Prim-
ers bsp22F (59-CACCATGAGCATTGATCTCG-39) and bsp22R (59-TTGCTC
CTGCATGGAATACT-39) were used to amplify the open reading frame (ORF)
of Bsp22 from B. pertussis Tohama I. The PCR assay was conducted in a final
volume of 20 ml with 0.5 U of Platinum Pfx polymerase (Invitrogen). The
amplified product of 727 bp was cloned first into the pENTR/SD/D-TOPO entry
vector and then into the Gateway pDEST17 destination vector according to the
manufacturer’s instructions (Invitrogen). The recombinant clones were con-
firmed by PCR and were sequenced. The pDEST17:bsp22 vector was trans-
formed first into TOP10 competent E. coli cells and then into BL21 Star (DE3)
host expression cells. For Bsp22 expression, a selected clone was grown in LB
medium containing ampicillin (100 mg ml21). When the cell culture reached an
optical density at 600 nm (OD600) of ;0.6, protein expression was induced with
isopropyl-b-D-thiogalactopyranoside (IPTG) at a final concentration of 1 mM,
and incubation was continued for another 3 h. E. coli cells were harvested and
resuspended in Laemmli buffer (26), and the total proteins in soluble whole
lysates were analyzed by sodium dodecyl sulfate-polyacrylamide gel electropho-
resis (SDS-PAGE). Electrophoresis was performed at room temperature and
constant voltage. Molecular weight was estimated by means of the GE calibration
kit, and proteins resolved on gels were visualized by using a Coomassie blue
staining method.
Purification of recombinant His6-Bsp22. For His6-Bsp22 purification, recom-
binant E. coli DE3 cells obtained from 100 ml of IPTG-induced cultures were
resuspended in 4 to 8 ml of denaturing lysis buffer (Invitrogen). The recombinant
protein was solubilized, and bacterial cells were disrupted by sonication (30-s
pulses with 30-s intervals for 5 min). After centrifugation, the resultant super-
natant was loaded onto Ni-nitrilotriacetic acid (NTA) columns (Invitrogen)
equilibrated in denaturing lysis buffer (Invitrogen). The recombinant protein was
purified under denaturing conditions (buffers used contained 8 M urea at dif-
ferent pH values ranging from 7.9 to 4.0). The purification steps were performed
according to the manufacturer’s protocols. Fractions containing recombinant
His6-Bsp22 were pooled and concentrated 16-fold using an Amicon Ultra-4 10K
centrifugal filter device (Millipore). The final product was judged to be pure by
SDS-PAGE. Fractions containing purified protein were dialyzed at 4°C against
phosphate-buffered saline (PBS) to remove urea from the preparation and were
stored at220°C until use. The identity of the expressed protein and its molecular
weight were confirmed by matrix-assisted laser desorption ionization–time of
flight (MALDI-TOF) mass spectrometry. The protein concentration of purified
His6-Bsp22 was determined by the Bradford method, with bovine serum albumin
as a standard (3).
Production of a polyclonal serum against His6-Bsp22. To obtain specific sera
against His6-Bsp22, 3 mice obtained from the Instituto Biolo´gico Argentino
(Biol. SAIC, Argentina) were immunized intraperitoneally twice, at intervals of
14 days, with 5 mg of the purified recombinant protein each time. Al(OH)3 was
used as an adjuvant. Fourteen days after the last immunization, mice were bled,
and the serum was prepared in order to assess the presence of specific circulating
antibodies against His6-Bsp22 by immunoblotting.
B. pertussis Dbsp22 mutant strain construction. Gentamicin-resistant Dbsp22
derivatives of B. pertussis Bp106 (Bp106 Dbsp22) were constructed as follows.
Two single-stranded oligonucleotide primers were designed on the basis of
the bsp22 sequence: bsp22RTF (59-AACTCCTCACGGCTCAAATG-39) and
bsp22RTR (59-ACGGTGGTGTAGGCACTTTC-39). Using these primers and
Taq DNA polymerase (0.5 U), we accordingly amplified a 346-bp fragment
corresponding to an internal sequence of the bsp22 gene by PCR. This PCR
product was cloned into the shuttle plasmid pGEM-T Easy (Apr lacZ). After
ligation, a recombinant fragment from this plasmid was released with EcoRI and
was cloned into the EcoRI site of the Bordetella suicide plasmid pG18mob (Gmr)
(25). The recombinant suicide plasmid pG18mob:bsp22 was transformed into
electrocompetent Bp106 cells, which were thereafter selected for single genetic
crossovers on BGA supplemented with 10 mg/ml gentamicin. A gentamicin-
resistant single recombinant of B. pertussis Bp106 was screened by PCR using
M13 and the bspRT22F/bspRT22R primers for the presence of the expected DNA
structure and was also analyzed by immunoblotting for Bsp22 expression.
RNA isolation and RT-qPCR. Total RNA from mid-log-phase bacterial cul-
tures was isolated using a commercial RNAspin Mini RNA isolation kit (GE
Healthcare) according to the manufacturer’s protocols. Reverse transcription-
quantitative PCR (RT-qPCR) was performed using 300 ng of total RNA and
Moloney murine leukemia virus reverse transcriptase (Promega). The resulting
cDNA was amplified in triplicate using a SYBR green PCR assay (Bio-Rad
Laboratories, Hercules, CA), and products were detected on an iQ5 cycler
(Bio-Rad). PCR samples were incubated for 4 min at 95°C, followed by 40
amplification cycles with 30 s of annealing/extension at 60°C and 15 s of dena-
turation at 95°C. For analysis of bscN and bscC gene transcription, the following
primers were used: bscNF (59-CATGCCCACAAGTTCTATCC-39)/bscNR (59-
GACCGAGTCCATCAGAAAAA-39) and bscCF (59-CCTTGATCGTGCAGG
ATATT-39)/bscCR (59-GGGTGCGAATGTAGAAGGTA-39). For analysis of
bsp22 gene transcription, the bspRT22F and bspRT22R primers, described above,
were used. PCR specificity was checked by melting curves. recA transcription was
used as a normalizer with primers recAF (59-AAGACCACGCTCACGCTGCA
GGTCA-39) and recAR (59-ATCAGCAGGTCGGTCAGGTTGACGC-39). The
relative mRNA expression levels of each gene in each sample were calculated
using the comparative threshold cycle (CT) method (35). The categorical vari-
ables were compared by using one-way analysis of variance with a Tukey posttest.
A P value of ,0.05 was considered statistically significant.
TABLE 1. Bordetella strains used in this study
Strain/clinical
isolate
Yr of
isolation prn ptx Origin Reference
Bb9.73 Collection de l’Institut
Pasteur
26a
Bb9.73 DbvgA Argentine 13
Bp18323 1947 prn6 ptxS1E United States 33a
Tohama I 1954 prn1 ptxS1C Japan 24
Bp10536 prn1 ptxS1A United States 34
Bp509 1950 prn7 ptxS1D Netherlands 18a
Bp6901 1969 prn1 ptxS1A Argentina 1
Bp8201 1982 prn1 ptxS1A Argentina 1
Bp005 2000 prn2 ptxS1A Argentina 1
Bp006 2000 prn2 ptxS1A Argentina 1
Bp007 2000 prn1 ptxS1A Argentina 1
Bp102 2001 prn1 ptxS1A Argentina 1
Bp106 2001 prn2 ptxS1A Argentina 1
Bp204 2002 prn2 ptxS1A Argentina 1
Bp301 2003 prn2 ptxS1A Argentina 1
Bp305 2003 prn2 ptxS1A Argentina 1
Bp314 2003 prn1 ptxS1A Argentina 1
Bp407 2004 prn2 ptxS1A Argentina 1
Bp506 2005 prn2 ptxS1A Argentina This study
Bp610 2006 prn2 ptxS1A Argentina This study
Bp708 2007 prn2 ptxS1A Argentina This study
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Immunoblot analysis. B. pertussis grown on BGA or SS liquid medium was
used for the different preparations. The whole-cell lysate was prepared as de-
scribed previously (14). To analyze supernatant fractions of Bordetella spp.,
bacteria were grown in SS medium in 100 ml of culture inoculated at a starting
OD650 of 0.20. Cultures were harvested for each bacterial strain at the same stage
of bacterial growth as determined by OD650 measurements. Cell-free superna-
tant fractions obtained after filtering through a 0.22-mm-pore-size polycarbonate
filter were precipitated with 10% (wt/vol) trichloroacetic acid at 4°C for 4 h and
were then resuspended in sample buffer. Bordetella sp. whole-cell lysates and
supernatants were transferred to a polyvinylidene difluoride (PVDF) membrane
(Immobilon P; Millipore). For this purpose, SDS-PAGE was performed accord-
ing to the method of Laemmli (26) using denaturing 15% (wt/vol) SDS-poly-
acrylamide gels. Proteins separated by SDS-PAGE were transferred to a poly-
vinylidene difluoride membrane (Immobilon P; Millipore) at a constant voltage
(100 V; 1 h) and were then probed either with a polyclonal anti-Bsp22 antibody
or with a polyclonal anti-PtxS1 antibody (diluted 1:500), followed by incubation
with anti-mouse IgG conjugated with alkaline phosphatase (AP) at a 1:1,000
dilution. Nitroblue tetrazolium (NBT)–5-bromo-4-chloro-3-indolylphosphate
(BCIP) was used as the AP substrate according to the manufacturer9s protocol
(Promega).
i.n. infection of mice with B. pertussis. Female BALB/c mice, 3 to 4 weeks of
age, obtained from the Instituto Biolo´gico Argentino (Biol. SAIC, Argentina)
were infected intranasally (i.n.) with 107 CFU of B. pertussis strain Tohama I, the
Bp106 clinical isolate, or its laboratory-adapted derivative strain (Bp106 after 35
passages) in 50 ml of a PBS suspension. Bacteria from glycerol stocks were
cultured on BGA (Difco) supplemented with 1% glycerol and 10% (vol/vol)
defibrinated sheep blood and were incubated at 36°C for 3 days. Then the
bacteria were replated in the same medium for 24 h, resuspended, and adjusted
to approximately 108 CFU ml21 in phosphate-buffered saline. Infections were
performed by pipetting the inoculum down into the nostrils. Animals were
sacrificed 8 days after infection, and lungs were excised for bacterial recovery as
described previously (1). The expression of Bsp22 in recovered bacteria was
evaluated by immunoblotting. At least two independent experiments were per-
formed.
RESULTS AND DISCUSSION
The reemergence of the disease called pertussis has been
attributed mainly to waning vaccine-induced immunity and
pathogen adaptation (31). Pathogen adaptation is supported
by the antigenic divergence observed between vaccine strains
and clinical isolates with respect to several vaccine compo-
nents, such as pertussis toxin (Ptx) and pertactin (Prn) (10, 14,
23, 30, 31, 39). In addition to antigenic variation, increased Ptx
production has been associated with the resurgence of pertus-
sis. Strains with a novel allele for the ptx promoter (ptxP3)
emerged in the 1990s, replacing the resident ptxP1 strains (32).
Sporadically, isolates obtained from pertussis patients do not
produce Prn or Ptx (2).
An interesting recent report demonstrates the secretion of
the Bordetella TTSS effector, Bsp22, by a significant number of
Irish B. pertussis clinical isolates but not by common laboratory-
adapted vaccine strains, such as Tohama I (12). Despite reports
describing the transcription of genes encoding components of
the Bordetella bsc TTSS machinery in B. pertussis Tohama I (9,
20, 27), studies performed before that of Fennelly et al. (12)
have failed to demonstrate TTSS effector secretion by B. per-
tussis either in vitro or in vivo (20, 27). Fennelly et al. suggested,
but did not demonstrate, that B. pertussis might lose the ca-
pacity to express TTSS proteins after prolonged in vitro culture
(12). In this work, we extended the analysis of TTSS protein
expression to Argentinean clinical isolates and evaluated the
previous hypothesis by performing successive in vitro cultures
and in vivo infection assays.
As a first step, we corroborated by quantitative PCR that a
laboratory-adapted vaccine strain (strain Tohama I) and a clin-
ical isolate (Bp106) representative of our bacterial collection
transcribe differential levels of mRNA for TTSS-associated
genes. In particular, we evaluated bscN, bscC, and bsp22
mRNA levels. Although both strains transcribed the three
genes analyzed, Bp106 showed higher mRNA levels than To-
hama I, and these differences were most pronounced for the
bsp22 gene (Fig. 1). Taking these results into account, we
decided to measure the expression of the TTSS in clinical
isolates by using the effector protein Bsp22 as a marker. To this
end, we performed immunoblot assays using a specific serum,
obtained from the recombinant His6-Bsp22 protein con-
structed here, whose identity was confirmed by MALDI-TOF
spectrometry. The specificity of the anti-Bsp22 serum against
the characteristic epitopes of wild-type Bsp22 protein and not
against the recombinant protein was evaluated through immu-
noblot assays using antigens derived from B. bronchiseptica. In
particular, we used the cell-free supernatant proteins from B.
bronchiseptica CIP 9.73 (Bb9.73) and its derivative BvgA-de-
fective mutant (Bb9.73 DbvgA), which is fixed in the well-
known phenotypic avirulent state (13). This mutant was em-
ployed for the assay because it had already been demonstrated
that TTSS is not expressed when the bacterium is in the avir-
ulent phase (27). We also included in the experiments the
supernatant proteins from the Bp106 clinical isolate and its
derivative Bsp22-defective mutant (Bp106 Dbsp22), obtained in
this work by site-specific insertional mutagenesis (Fig. 2). As
shown in Fig. 2, the anti-Bsp22 serum recognized a band with
the expected molecular size for Bsp22 in the parental Bb9.73
and Bp106 strains but not in either defective mutant (Bb9.73
DbvgA or Bp106 Dbsp22).
For immunoblotting using the specific anti-Bsp22 polyclonal
serum, cell-free supernatant proteins from 15 selected B. per-
tussis clinical isolates in our collection with different genotypic
characteristics, obtained during the years 1969 to 2007, were
used (Table 1). As shown in Fig. 3, the specific serum reacted
against a protein with the expected molecular size of 22 kDa in
all clinical isolates assayed, independently of the year of isola-
tion or genotypic characteristics. As expected, this Bsp22-spe-
cific antiserum, which recognized the presence of Bsp22 in B.
bronchiseptica, did not react with samples obtained from ref-
FIG. 1. Quantitative PCR analysis of bscN, bscC, and bsp22 tran-
script levels in the vaccine strain Tohama I and the clinical isolate
Bp106. cDNA obtained from total RNA of Tohama I and Bp106 was
used as a template for PCR. The recA transcript was used as a refer-
ence. Comparisons of Tohama I with Bp106 were performed for each
gene evaluated; P values were ,0.05 (a and b) and ,0.01 (c).
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erence strains, such as Tohama I or Bp18323 (the WHO ref-
erence strain), or vaccine strains, such as Bp10536 and Bp509
(Fig. 3). To assess whether the expression of the system in
these isolates was lost after they were adapted to in vitro cul-
ture conditions, we selected a subset of isolates (Bp106,
Bp6901, and Tohama I) to be subjected to 35 successive pas-
sages in vitro. In these bacteria, TTSS expression was again
assessed by immunoblot assays for the Bsp22 protein (Fig. 4).
Interestingly, while all the bacteria studied expressed Ptx,
TTSS expression was observed only in clinical isolates recently
obtained from the host, not in long-term laboratory-adapted
cultures (Fig. 4A). In fact, TTSS expression was already lost at
the 5th in vitro passage (Fig. 4B). In contrast, strain Tohama I,
which has been extensively grown through laboratory passages
since its isolation in Japan in 1954 (24), did not express Bsp22
protein in any of the culture steps assessed. To establish pre-
cisely in which passage the expression of Bsp22 in Bp106 is lost,
we performed a new immunoblot assay for passages 1 to 5 (Fig.
5). As can be seen in Fig. 5, Bsp22 expression stops between
passages 3 and 4. As a control for all immunoblot assays per-
formed, we included Bsp22 recombinant protein obtained
from an engineered E. coli strain constructed by us.
These results demonstrating the inability of in vitro culture-
adapted bacteria to express the marker Bsp22 raise the ques-
tion of whether these laboratory species, including the vaccine
strain Tohama I, are able to reexpress the TTSS effector Bsp22
when they regain contact with the host. To check this phenom-
enon, mice were infected with laboratory-adapted or non-
adapted bacteria and were sacrificed 8 days after infection in
order to test the abilities of the microorganisms recovered
from their lungs to express Bsp22. Immunoblot assays using
the Bsp22-specific antiserum showed that both laboratory-
adapted clinical isolates and the vaccine strain Tohama I were
now able to express proteins of the TTSS system (Fig. 6).
Taken together, the results presented here not only confirm
that the expression of TTSS is a feature of natural B. pertussis
FIG. 2. Reactivities of an anti-Bsp22 serum against supernatant
proteins from B. bronchiseptica and B. pertussis strains. Proteins from
B. bronchiseptica 9.73 grown under Bvg1 conditions (Bb9.73 BvgAS1)
and from its avirulent constitutive derivative mutant (Bb9.73 DbvgA)
(A) and from a Bsp22-defective mutant of B. pertussis Bp106 (Bp106
Dbsp22) and its parental strain Bp106 (B) were resolved by 15% (wt/
vol) SDS-PAGE (left) and were probed with the indicated sera (right).
Purified His6-Bsp22 and Ptx were used as positive controls.
FIG. 3. Immunoblot analysis of supernatant proteins from Argentinean B. pertussis clinical isolates and laboratory-adapted strains. Proteins
from reference and vaccine strains (A) and from clinical isolates (B) were resolved by 15% (wt/vol) SDS-PAGE, transferred to a PVDF membrane,
and probed with a polyclonal serum specific for Bsp22. Samples in panel A were also probed with a polyclonal antiserum specific for subunit S1
of pertussis toxin (PtxS1). Positive controls were purified recombinant His6-Bsp22 and PtxS1 proteins, as well as samples obtained from B.
bronchiseptica strain 9.73 (Bb9.73) and the clinical isolate Bp106.
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infection but also demonstrate the reversibility of the expres-
sion system depending on whether the bacteria do or do not
come into contact with the host. Even though this work was not
intended to elucidate the molecular mechanism of the phe-
nomenon demonstrated, some evidence indicates that B. per-
tussis, a pathogen with little gene loss or gain, can generate
biodiversity by rearranging its chromosome and altering gene
expression (4, 36, 37). For example, it has been reported re-
cently (19) that an IS481 insertion could cause the differential
expression of the TTSS cytotoxic effector protein BteA in clin-
ical isolates of B. pertussis. This protein is expressed at higher
levels in B. pertussis non-vaccine-type strains than in vaccine-
type strains. This type-dependent expression suggests that the
increased BteA protein level might play a key role in the type
shift of B. pertussis (19). It would be interesting to analyze if
this mechanism could be involved in the expression switch of
the TTSS between in vivo and in vitro conditions. Indepen-
dently of the mechanism involved, the findings of this paper
represent concrete evidence for an intuitively expected feature
that has been described in other pathogens (15, 41, 43): dif-
ferential protein expression between bacteria grown under in
vitro versus in vivo conditions. However, the outcome of our
experiments is particularly relevant for the pertussis scenario,
where the well-documented genomic divergence between vac-
cine strains (adapted to the laboratory) and bacteria recently
isolated from the host (clinical isolates) might render control
of the disease difficult. The in vivo/in vitro differences reported
here add a new layer of complexity that should be taken into
account in designing novel formulations, since current vac-
cines, based on strains subcultured extensively in vitro, might
not reflect the real protein profile of the pathogen under in
vivo conditions.
FIG. 4. Immunoblot analysis of laboratory-adapted B. pertussis isolates/strains for TTSS expression. (A) Supernatant proteins of B. pertussis
strains Bp6901, Bp106, and Tohama I with their derivatives obtained after 35 successive in vitro passages (Adapted). (B) TTSS expression through
35 in vitro passages of Bp106. The sera used in immunoblotting are indicated on the left.
FIG. 5. Immunoblot analysis of TTSS expression through 5 in vitro
passages of Bp106. Supernatant proteins of B. pertussis Bp106 with
their derivatives obtained after 5 successive in vitro passages were
resolved by 15% (wt/vol) SDS-PAGE, transferred to a PVDF mem-
brane, and probed with a polyclonal serum specific for Bsp22. Samples
were also probed with a polyclonal antiserum specific for subunit S1 of
pertussis toxin (PtxS1). Purified recombinant His6-Bsp22 and PtxS1
proteins were included in this assay as positive controls.
FIG. 6. Analysis of TTSS expression in vivo. Protein samples ob-
tained from B. pertussis supernatant cultures (in vitro) or from whole-
cell bacteria recovered from infected mice (in vivo) were analyzed for
Bsp22 expression by immunoblotting. Samples obtained from Tohama
I, Bp106 (Bp106 Not Adapted), and isolate Bp106 subjected to 35 in
vitro passages (Bp106 Adapted) were probed with a polyclonal antise-
rum specific for Bsp22 or subunit S1 of pertussis toxin (PtxS1). Purified
His6-Bsp22 and Ptx were used as positive controls.
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